![]() ![]() Development and investigations are underway for antidotes to reverse all available DOACs, yet thus far the US Food and Drug Administration (FDA) has approved only one agent that specifically reverses dabigatran etexilate mesylate, or Pradaxa (Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn). Introduction: Dabigatran, a direct thrombin inhibitor, is 80 renally eliminated and demonstrates multi-compartmental pharmacokinetics. In the rare event of an extensive bleed, an effective antidote for the anticoagulant is desired. Pradaxa treatment can be initiated 24 hours after administration of PRAXBIND see Clinical Pharmacology (12.2). While the DOAC agents have demonstrated similar or a statistically reduced risk for major bleeding compared with warfarin in clinical trials for treatment of nonvalvular atrial fibrillation and venous thromboembolism, bleeding remains a concern with all anticoagulants. Data Sources: Articles for this review were. The approval of the first reversal agent in the US for a direct oral anticoagulant (DOAC) propels the evolution of patient care for those who require anticoagulation. Objective: To review clinical data on idarucizumab for the reversal of dabigatran-associated anticoagulation. The use of anticoagulants that directly affect thrombin, or the clotting factor Xa, has become mainstream practice over the past few years, often replacing warfarin as first-line therapy. Praxbind is a specific reversal agent for dabigatran and indicated in adult patients treated with Pradaxa (dabigatran etexilate), when rapid reversal is required. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |